Skip to content

Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study

Polycystic Ovarian Syndrome (PCOS) in Human Adolescent and Young Adult Females - Biomarker Evaluation Study (PHOEBE)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06642831
Acronym
PHOEBE
Enrollment
380
Registered
2024-10-15
Start date
2023-01-31
Completion date
2027-03-31
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome (PCOS)

Keywords

PCOS, biomarker, adolescents

Brief summary

The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.

Detailed description

The purpose of the study is to validate potential biomarkers for the aid in the diagnosis of PCOS in adolescent and young adult women in the age range of 15-25 years. Female subjects included in this study will have one visit where clinical data for assessing PCOS will be collected and a blood draw will be performed to collect serum for measurement of parameters relevant to PCOS will be performed. Study subjects that receive a PCOS diagnosis will have two follow up visits for follow up on treatment where additional serum and clinical data will be collected. The first visit will be 3 months after receiving the diagnosis and the second visit 6-12 months after the initial visit.

Interventions

None listed

Sponsors

Roche Diagnostics International AG
CollaboratorINDUSTRY
University Hospital Erlangen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
15 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Female subjects age 15-25 years * Signed written informed consent

Exclusion criteria

* Less than 1 years from onset of menarche * Use of hormonal contraceptives * Documented ongoing pregnancy * Major ovarian abnormalities, including subject with only one ovary, cysts and solid masses \> 2 cm as detected by transvaginal ultrasound * Malignancy ( documented malignancy, documentation of current radiation therapy or chemotherapy in medical record)

Design outcomes

Primary

MeasureTime frame
The validation of new potential biomarkers for aid in the diagnoisis of PCOS in adolescent and young adult womenBaseline

Countries

Germany

Contacts

Primary ContactLaura Lotz, Dr. med.
laura.lotz@uk-erlangen.de+49 9131 85 44023
Backup ContactRalf Dittrich, Prof.
ralf.dittrich@uk-erlangen.de

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026